AN2 Therapeutics Appoints Cameron Trenor, M.D., as Chief Medical Officer to Advance Clinical Development Pipeline
AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing novel small molecule therapeutics through its proprietary boron chemistry platform, has announced the appointment of Cameron Trenor, M.D., as Chief Medical Officer. The appointment brings an experienced physician-scientist and biotechnology executive to AN2 Therapeutics as the company continues to advance its pipeline of innovative therapies through clinical development.
Dr. Trenor brings more than two decades of experience spanning clinical and translational research and development across a broad range of therapeutic areas, including hematology, rare diseases, oncology, immunology and metabolic disorders. Throughout his career, he has contributed to the advancement of novel medicines from early discovery and translational research through clinical development, regulatory engagement and commercialization planning.
His appointment comes at an important stage for AN2 Therapeutics as the company works to translate its scientific platform into potential treatments for patients with significant unmet medical needs. As Chief Medical Officer, Trenor will be responsible for helping guide the company’s clinical strategy and development programs, while working closely with research teams, regulatory agencies, investigators and patient communities.
Experienced Physician-Scientist Joins AN2 Therapeutics
Eric Easom, Co-Founder, President and Chief Executive Officer of AN2 Therapeutics, welcomed Trenor to the company and highlighted his experience in building clinical organizations and advancing innovative therapies.
According to Easom, Trenor’s background will be particularly valuable as AN2 continues to expand its pipeline and progress its programs through development. His experience working across biotechnology companies and large pharmaceutical organizations provides him with an understanding of the different challenges involved in moving experimental medicines from scientific discovery into clinical testing and, ultimately, toward potential commercialization.
Easom also emphasized Trenor’s scientific approach and patient-focused perspective. The company believes these qualities will complement AN2’s existing leadership and help strengthen its ability to execute clinical development strategies.
The appointment also marks a transition in AN2 Therapeutics’ clinical leadership. The company expressed its appreciation to George H. Talbot, M.D., Co-Founder and Senior Scientific Advisor of AN2 Therapeutics, for his leadership of the company’s clinical programs over the past two years.
Talbot has played an important role in the development of AN2 from its earliest stages and has contributed to the company’s clinical programs since its founding. He will continue to support AN2 as a strategic advisor, helping provide continuity and scientific guidance as Trenor assumes his new responsibilities.
Easom thanked Talbot for his contributions and continued commitment to the company, noting that his involvement has been important to AN2 from its earliest days.
Broad Clinical Development Experience
Trenor joins AN2 with extensive experience across multiple stages of drug development. Most recently, he served as Chief Medical Officer of Cellarity, where he helped establish the company’s medical organization as it transitioned into a clinical-stage biotechnology company.
At Cellarity, Trenor was responsible for overseeing the development of the company’s lead program. His responsibilities included guiding the program through its first Investigational New Drug (IND) submission and supporting the initiation of a global first-in-human clinical study.
The transition from a discovery-focused biotechnology company into a clinical-stage organization can require substantial changes in operational infrastructure, clinical strategy and regulatory planning. Trenor’s experience during this period provides relevant expertise as AN2 continues to develop its own clinical programs.
At Cellarity, he helped build the medical capabilities necessary to support clinical development and establish the processes required to move an innovative therapeutic candidate into human testing.
Before joining Cellarity, Trenor served as Executive Medical Director at Forma Therapeutics, a biotechnology company that was subsequently acquired by Novo Nordisk. At Forma, he was involved in global clinical development activities for etavopivat, an investigational therapy evaluated across multiple indications.
His responsibilities included helping advance etavopivat from early clinical development into Phase 3. This experience provided Trenor with exposure to the increasingly complex clinical, regulatory and operational requirements associated with late-stage development.
Experience Across Hematology and Rare Diseases
Earlier in his career, Trenor held leadership positions at Novartis Institutes for BioMedical Research, where he led clinical and translational development programs in hematology and rare diseases.
His work in these areas has given him experience with diseases in which the development of new treatments can require a deep understanding of disease biology, patient populations and specialized clinical endpoints.
Hematology and rare disease development also frequently involves close collaboration among academic researchers, specialist physicians, patient advocacy organizations and regulatory authorities. Trenor’s experience working across these groups has contributed to his broader understanding of patient-centered clinical development.
His professional background extends across oncology, immunology and metabolic disorders, giving him exposure to diverse therapeutic mechanisms and development strategies.
This multidisciplinary experience is expected to support his work at AN2 Therapeutics as the company evaluates and advances therapies derived from its boron chemistry platform.
AN2’s Boron Chemistry Platform
AN2 Therapeutics is developing novel small molecule medicines based on its proprietary boron chemistry platform. The company is focused on using this technology to identify and develop potential therapies for diseases where significant unmet medical needs remain.
Small molecule therapeutics can offer a number of potential advantages in drug development, including the ability to target specific biological pathways and, depending on the candidate, the potential for convenient administration and distribution into relevant tissues.
AN2’s boron chemistry platform is intended to provide the foundation for discovering and optimizing new therapeutic compounds. As the company advances its pipeline, clinical development leadership will be important for determining how promising candidates should be evaluated in human studies.
Trenor’s background in translational medicine is particularly relevant to this stage of development because successful clinical programs require a connection between laboratory findings and patient outcomes. Translational development helps determine how preclinical evidence can be converted into appropriate clinical hypotheses, endpoints and study designs.
Focus on Clinical and Regulatory Strategy
As Chief Medical Officer, Trenor will be expected to play a central role in shaping AN2 Therapeutics’ clinical development strategy. His responsibilities will include supporting clinical program design, medical oversight, interactions with regulatory authorities and collaboration with investigators involved in clinical studies.
His previous experience with regulatory interactions and IND submissions is particularly relevant as AN2 continues to move programs forward. Regulatory engagement is a critical part of drug development because companies must demonstrate that clinical studies are appropriately designed and that potential benefits justify continued investigation.
Trenor’s experience leading programs from early clinical development through later-stage studies also provides insight into how clinical strategies may need to evolve as evidence accumulates.
Early clinical studies generally focus on safety, tolerability, pharmacokinetics and establishing appropriate dosing. Later-stage programs require increasingly robust evidence of efficacy and may involve larger patient populations and more complex trial designs.
Having worked across these different stages, Trenor brings an understanding of the long-term development pathway required to potentially transform an experimental compound into an approved therapy.
Continuing Connection to Patient Care
In addition to his biotechnology leadership experience, Trenor remains a practicing pediatric hematologist-oncologist at Boston Children’s Hospital. His continued clinical practice provides a direct connection to patients and the realities of treating serious diseases.
This clinical perspective can be valuable in drug development, particularly when determining whether an investigational treatment addresses a meaningful medical need and whether clinical trial designs reflect the experiences and priorities of patients.
Maintaining involvement in patient care also provides exposure to the challenges faced by families navigating complex diseases and treatment decisions. This experience complements Trenor’s industry background and supports a patient-centered approach to clinical development.
Academic and Scientific Background
Trenor has authored approximately 60 peer-reviewed research publications, reflecting his longstanding involvement in scientific and clinical research.
He earned a Bachelor of Science degree in Biology from Tufts University before receiving his Doctor of Medicine degree from the University of Tennessee College of Medicine. He subsequently completed a Master of Medical Sciences degree in Clinical Investigation at Harvard Medical School.
His postgraduate medical training included residency and fellowship programs through Boston Children’s Hospital, Boston Medical Center and Dana-Farber Cancer Institute. He is board-certified in Pediatric Hematology-Oncology.
This combination of academic training, clinical practice and industry experience has shaped his career as a physician-scientist focused on translating biomedical research into potential new treatments.
Strengthening AN2’s Executive Leadership
The appointment of Trenor adds significant clinical development expertise to AN2 Therapeutics’ executive leadership team. His experience spans emerging biotechnology companies, established pharmaceutical organizations and academic medicine, providing a broad perspective on the development of innovative medicines.
For a clinical-stage company, the Chief Medical Officer plays a critical role in connecting scientific strategy with clinical execution. This includes identifying appropriate development pathways, designing clinical studies, overseeing medical aspects of trials and helping communicate clinical data to regulators, investigators and other stakeholders.
Trenor’s prior experience establishing a medical organization at Cellarity may also be valuable as AN2 expands its clinical infrastructure. Building an effective clinical organization requires coordination across medical affairs, clinical operations, regulatory affairs, data management and other functions.
His experience working with global clinical programs is expected to further support AN2 as the company advances its development activities.
The appointment comes as AN2 Therapeutics continues to develop its pipeline and seek opportunities to translate its proprietary boron chemistry platform into new treatment options.
With more than 20 years of experience in clinical and translational development, Trenor brings expertise across early research, clinical trials, regulatory engagement and late-stage development. His background includes work across hematology, rare diseases, oncology, immunology and metabolic disorders, as well as leadership experience at both biotechnology and pharmaceutical organizations.
AN2 believes his combination of scientific expertise, clinical experience and industry leadership will help the company advance its pipeline while maintaining a strong focus on patients.
Meanwhile, George H. Talbot will continue supporting the company as a Senior Scientific Advisor and strategic advisor following his leadership of AN2’s clinical programs during the past two years. His continued involvement provides the company with access to his experience and institutional knowledge as the leadership transition takes place.
For AN2 Therapeutics, the addition of Trenor represents an important investment in clinical development capabilities. As the company progresses from scientific research toward potentially transformative therapies, experienced clinical leadership will be essential to translating its proprietary technology into medicines that can ultimately benefit patients.
With Trenor now serving as Chief Medical Officer, AN2 Therapeutics is positioned to further strengthen its clinical strategy, advance its pipeline and pursue the next stages of development for its novel small molecule therapeutics. His combination of physician expertise, translational research experience and biotechnology leadership is expected to support the company’s continued evolution as it works to bring innovative treatments to patients with significant unmet medical needs.
About AN2 Therapeutics
AN2 Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on the discovery and development of novel small molecule therapeutics derived from our boron chemistry platform. Our development pipeline spans hematologic diseases, infectious diseases, and oncology with three Phase 2 studies expected to be active in 2026, two preclinical oncology candidates, as well as advanced research programs focused on targets in oncology, bone disorders, and infectious diseases. We are committed to delivering high-impact drugs to patients that address critical unmet needs and improve health outcomes.